• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Johnson & Johnson

Johnson & Johnson

Johnson & Johnson JNJ 2 Star

Last Price$108.04Day Change (%)0.64%
Open Price$107.89Day Change ($)0.69
Day Range107.72–108.3352-Week Range85.50–108.33

As of Fri 09/19/2014 12:28 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

    Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

  2. Johnson & Johnson to Participate in 2014 Morgan Stanley Health Care Conference

    Johnson & Johnson to Participate in 2014 Morgan Stanley Health Care Conference

  3. We Are Mesh Survivors Applauds Verdict against Johnson and Johnson on Pelvic Mesh: Jury Delivers $3.27 Million Verdict for Plaintiff Jo Huskey in Johnson & Johnson Federal Trial on Pelvic Mesh ...

    We Are Mesh Survivors Applauds Verdict against Johnson and Johnson on Pelvic Mesh: Jury Delivers $3.27 Million Verdict for Plaintiff Jo Huskey in Johnson & Johnson Federal Trial on Pelvic Mesh Devices in West Virginia

  4. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.

  5. Peters: Know What You Want From Dividend ETFs

    There can be good reasons to own dividend-focused ETFs, but investors looking for pure income may be better off in individual stocks, says Morningstar's Josh Peters.

  6. Big Plans for New EU President Juncker

    Our model portfolio continues to outpace the market.

  7. J &J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover.

  8. Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK, J &J Merck & Pfizer

    Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK, J & J Merck & Pfizer

  9. Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles

    Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles

  10. Top 10 Buys and Sells by the Ultimate Stock-Pickers

    A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.